BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 3, 2016
View Archived Issues
Phase I studies show target engagement, acute GI symptoms with NexVax2 in HLA DQ2.5 celiac disease
Read More
BioRap and Pfizer enter agreement to develop new immunomodulators
Read More
NanoViricides enters partnership to further FluCide-I program
Read More
Grunenthal licenses European and Latin American rights to Zurampic from AstraZeneca
Read More
Incyte establishes collaboration to conduct several Moffitt blood cancer research programs
Read More
Dermira reports topline results from pivotal trials of DRM-04 for primary axillary hyperhidrosis
Read More
RegeneRx Biopharmaceuticals and Lee's Pharmaceutical accelerate development of RGN-259
Read More
Novartis plans phase III trials of subcutaneous ofatumumab in relapsing MS
Read More
BGN gene defects may cause an X-linked syndromic form of severe TAAD
Read More
FDA grants rare pediatric disease designation to Therabron's rhCC10
Read More
Corcept Therapeutics updates status of cortisol modulation programs in oncology
Read More
University College Cardiff Consultants patents AR modulators
Read More
Merck & Co. discloses sGC activators
Read More
Takeda Pharmaceutical describes GPR139 agonists
Read More
Eli Lilly and Company develops PKC inhibitors
Read More
Esteve presents dual sigma1 and mu-opioid receptor ligands
Read More
Pharosgen patent reveals anticancer agents
Read More
Shire completes combination with Baxalta
Read More
Deutetrabenazine shows promise for the treatment of for TD-related abnormal involuntary movements
Read More
Vectura's phase I trial of VR-942 meets primary objective
Read More
CSF exposure and proof of mechanism seen for cognitive impairment treatment BI-425809
Read More
Bellicum Pharmaceuticals enters research agreement with LUMC
Read More
Treos Bio developing precision cancer vaccines paired to companion diagnostics
Read More
Kiadis plans European MAA for ATIR-101
Read More
Astellas and Medivation plan phase III trial of enzalutamide for triple-negative breast cancer
Read More
Nektar Therapeutics reaches agreement with Daiichi Sankyo Europe for Onzeald
Read More